Aurinia Pharmaceuticals Inc Stock News

The biotech's underwhelming revenue guidance for 2022 is causing some shareholders to throw in the towel today.

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ: LXRX ) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (NASDAQ: PRAX ) is likely to report earnings for its fourth quarter. • Blackstone Secured (NYSE: BXSL ) is likely to report quarterly earnings at $0.59 per share on revenue of $171.69 million. • Mersana Therapeutics (NASDAQ: MRSN ) is estimated to report earnings for its fourth quarter. • Partner Communications Co (NASDAQ: PTNR ) is expected to report earnings for its fourth quarter. • Daqo New Energy (NYSE: DQ ) is expected to report quarterly earnings at $4.58 per share on revenue of $698.65 million. • Easterly Government Props (NYSE: DEA ) is likely to report quarterly earnings at $0.10 per share on revenue of $72.20 million. • Aurinia Pharmaceuticals (NASDAQ: AUPH ) is expected to report earnings for its fourth quarter. • Kosmos Energy (NYSE: KOS ) is estimated to report quarterly earnings at $0.15 per share on revenue of $380.

Aurinia (AUPH) delivered earnings and revenue surprises of 3.85% and 4.34%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q4 earnings results on Monday, February 28th, before market open.The consensus EPS Estimate is -$0.27 and the consensus…

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

A whale with a lot of money to spend has taken a noticeably bullish stance on Aurinia Pharmaceuticals . Looking at options history for Aurinia Pharmaceuticals (NASDAQ: AUPH ) we detected 12 strange trades. If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish expectations and 33% with bearish. From the overall spotted trades, 2 are puts, for a total amount of $81,447 and 10, calls, for a total amount of $474,702. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price … Full story available on Benzinga.com

Aurinia Pharmaceuticals <> is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release…

The company has several interesting companies on its short list.

Prices look like they can bounce further to the upside in the short-run but the longer-term picture is problematic….AUPH

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its fourth quarter and year end 2021 financial results

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation at the 11th Annual L

6 Top Biotech Ideas For 2022